Cyclosporine Market Size & Share 2026-2035

Cyclosporine Market Size

The cyclosporine market was valued at USD 3.8 billion in 2025. The market is estimated to grow from USD 4.2 billion in 2026 to USD 14.7 billion in 2035, growing at a CAGR of 14.8% over the analysis period, according to the latest report published by Global Market Insights Inc.

This market growth is driven by increasing demand for organ transplantation procedures. For instance, the United Network for Organ Sharing (UNOS) announced that 48,149 organ transplants were performed in 2024 in the U.S., according to data from the Organ Procurement and Transplantation Network (OPTN). Similarly, a total of 46,632 organ transplants were performed in 2023, marking an 8.7% increase from 2022 and a 12.7% increase from 2021. As cyclosporine is a critical immunosuppressant used to prevent organ rejection, the growing number of organ transplantation procedures is increasing the demand for cyclosporine, thus supporting market growth.

Additionally, the rising prevalence of autoimmune disorders, such as rheumatoid arthritis and psoriasis, has further fueled the demand for cyclosporine as a therapeutic agent. Moreover, expanding healthcare access in emerging economies, coupled with increasing investment in research and development for immunosuppressive therapies, supports the market's expansion. Growing awareness about organ donation and advancements in transplant technologies also bolsters the cyclosporine market globally.

Cyclosporine is an immunosuppressive agent used primarily to prevent organ rejection in transplant patients and to treat certain autoimmune diseases. It functions by inhibiting the activity of T-lymphocytes, which are central to the immune response. It is often prescribed for patients who have undergone kidney, liver, or heart transplants to prevent organ rejection. It is also prescribed for the treatment of conditions such as rheumatoid arthritis, psoriasis, and certain ophthalmic disorders such as dry eye disease.

Moreover, the cyclosporine market has registered significant growth between 2022 and 2024, increasing from 2.6 billion USD in 2022 to 3.3 billion USD in 2024. This can be attributed to the increasing prevalence of autoimmune conditions, rising organ transplant cases that require long-term immunosuppressive therapy, increasing use of cyclosporine in ophthalmic conditions such as dry eye disease and allergic keratoconjunctivitis, and the introduction of new formulations of cyclosporine, which have been designed to improve compliance and efficacy of the drug for patients suffering from the above conditions.

Cyclosporine Market Trends

• The increasing incidence of autoimmune disorders is one of the most prominent factors contributing to the cyclosporine industry. 
   
• As per the Institute for Health Metrics and Evaluation, as of 2020, approximately 17.6 million people worldwide were estimated to have rheumatoid arthritis. By 2050, it is forecasted that the number of individuals living with RA could rise to 31.7 million globally.
   
• Similarly, approximately 125 million people worldwide are affected by psoriasis, which accounts for about 2-3% of the global population.
   
• Autoimmune diseases, such as rheumatoid arthritis and psoriasis, occur when the immune system mistakenly attacks healthy cells, leading to chronic inflammation and tissue damage.
   
• Cyclosporine, an immunosuppressive drug, is widely used to manage these conditions by modulating immune responses and reducing the activity of overactive immune cells.
   
• As the global incidence of autoimmune diseases continues to rise, fueled by genetic predisposition, environmental triggers, and lifestyle changes, the demand for effective treatment options like cyclosporine is increasing.
   
• Furthermore, advancements in diagnostic techniques are improving early detection rates, expanding the patient pool requiring cyclosporine therapy, thereby bolstering market growth.
   

Cyclosporine Market Analysis

Based on the indication, the market is segmented into transplant rejection prophylaxis, rheumatoid arthritis, psoriasis, autoimmune myasthenia gravis, dry eye, and other indications. The transplant rejection prophylaxis segment dominated the market and was valued at USD 1.4 billion in 2025.
 

• The transplant rejection prophylaxis segment holds a significant share of the cyclosporine market, driven by its critical role in preventing organ rejection in transplant patients.
   
• Additionally, the high number of organ transplants, such as kidney, liver, and heart transplants, coupled with advancements in surgical techniques and post-transplant care, has contributed to the growing demand for effective prophylactic therapies.
   
• For example, Mayo Clinic Transplant achieved the highest annual transplant volume in its history in 2025 by performing 2,065 solid organ transplants across its Arizona, Florida, and Minnesota campuses, according to data from the Organ Procurement and Transplantation Network (OPTN).
   
• Furthermore, the segment benefits from established clinical guidelines that prioritize cyclosporine as a first-line therapy, further solidifying its market dominance.
   
• The dry eye segment is expected to witness rapid growth at a CAGR of 15.2% over the forecast years, driven by the rising global prevalence of dry eye disease, increasing digital screen exposure, growing aging population, and expanding adoption of cyclosporine ophthalmic formulations for long-term ocular surface inflammation management.

Based on the dosage form, the global cyclosporine market is categorized into capsules, eye drops, solutions, and creams and ointments. The capsule segment accounted for the highest market share of 31.7% in 2025.
 

• Capsules are preferred over other dosage forms as they provide better patient compliance, especially for long-term therapies required in conditions like organ transplantation and autoimmune diseases.
   
• Furthermore, advancements in encapsulation technologies ensure enhanced bioavailability and stability of cyclosporine, boosting the segment's demand.
   
• The growing prevalence of chronic conditions necessitating immunosuppressive therapies and the availability of generic capsule formulations have further contributed to the dominance of this segment.
   

Based on the route of administration, the market is categorized into oral, topical, and parenteral. The oral segment is anticipated to witness high growth, reaching USD 6.3 billion by 2035.
 

• The oral segment holds a significant share in the cyclosporine market, driven by its ease of administration, improved patient compliance, and consistent bioavailability.
   
• Oral formulations, such as capsules and oral solutions, are widely preferred for long-term therapy in chronic conditions like organ transplantation and autoimmune diseases, including rheumatoid arthritis and psoriasis.
   
• The segment's dominance is further supported by advancements in drug delivery technologies, ensuring better absorption and reduced side effects.
   
• The topical segment is also anticipated to witness strong growth owing to its targeted drug delivery, improved safety compared to systemic therapy, and increasing adoption in ophthalmic and dermatologic indications.
   

Based on the distribution channel, the global cyclosporine market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is anticipated to grow at a CAGR of 14.5% between 2026 - 2035.
 

• Hospitals serve as primary centers for organ transplantation procedures, where cyclosporine is a critical component of immunosuppressive therapy to prevent graft rejection. Additionally, the availability of specialized medical teams in hospitals ensures precise dosage and administration, enhancing patient outcomes.
   
• The integration of advanced drug dispensing systems and robust inventory management in hospital pharmacies further supports the accessibility and efficiency of cyclosporine distribution.
   
• This strong alignment with critical healthcare needs and infrastructure cements the dominance of hospital pharmacies in the cyclosporine market.
   
• The online pharmacies segment is projected to reach USD 2.4 billion by 2035, driven by growing patient preference for home delivery, increasing penetration of digital health platforms, improved medication accessibility in remote areas, and the rising adoption of e-commerce channels.

North America Cyclosporine Market
 

In 2025, North America dominated the global cyclosporine industry with a share of 36.8% and is anticipated to witness robust growth over the analysis timeframe.
 

• North America holds a dominant share in the global cyclosporine market, supported by strong clinical demand across transplantation and ophthalmology indications.
   
• In the U.S., a key regional contributor, more than 48,000 organ transplants were performed in 2024, reflecting sustained growth in transplant activity and a large patient population requiring lifelong immunosuppressive therapy such as cyclosporine.
   
• Additionally, government-reported data indicate over 45,000 transplants in 2023 and continued increases in organ donation and transplantation volumes, highlighting a robust treatment base driving immunosuppressant utilization.
   
• In addition, a high burden of ocular surface disorders supports cyclosporine uptake across outpatient settings.
   
• Thus, advanced healthcare infrastructure, strong reimbursement coverage, and high procedure volumes strengthen North America’s leading position in the global market.
   

The U.S. held a significant position in the North America cyclosporine market and was valued at USD 0.9 billion and USD 1 billion in 2022 and 2023, respectively. The market size reached USD 1.3 billion in 2025, growing from USD 1.1 billion in 2024.
 

• A well-established healthcare infrastructure, high adoption rates of immunosuppressive therapies, and the prevalence of chronic conditions such as autoimmune disorders and organ transplant requirements contribute to the strong market presence.
   
• For instance, approximately 1.3 million adults in the U.S. suffer from rheumatoid arthritis, which represents about 0.6% to 1% of the adult population. Furthermore, approximately 3.0% of U.S. adults aged 20 years and older have psoriasis, translating to over 7.5 million individuals affected.
   
• The presence of major players, extensive research and development activities, and favorable reimbursement policies further bolster the market's growth.
   

Europe Cyclosporine Market
 

Europe accounts for a significant share of the global cyclosporine industry due to well-developed transplant procedures and specialty care infrastructure, along with the rising rates of autoimmune and ocular diseases within the region.
 

• According to the Newsletter Transplant 2024 published by the EDQM of the Council of Europe, 42,576 organ transplants were performed in 1,040 transplantation centers across Council of Europe member states in 2023.
   
• This shows the sizeable patient population within the region requiring maintenance immunosuppressant agents like cyclosporine.
   
• In addition to this, universal access to healthcare within the region and growing rates of diagnosis of chronic inflammatory and ocular surface diseases further support the growth of the cyclosporine market within the region.
   

Germany shows strong growth potential in the cyclosporine market.
 

• Germany holds a significant position in the Europe market, driven by its robust healthcare infrastructure and advanced pharmaceutical manufacturing capabilities.
   
• Additionally, Germany's aging population and the increasing prevalence of chronic conditions such as organ transplantation and autoimmune diseases contribute to the high demand for immunosuppressive therapies like cyclosporine.
   

Asia Pacific Cyclosporine Market
 

The Asia Pacific market is estimated to grow at a CAGR of 15.4% over the next few years.
 

• The rising adoption of immunosuppressive therapies, supported by government initiatives and expanding healthcare access, is contributing to market growth.
   
• Additionally, the increasing number of transplant surgeries and advancements in medical technologies in countries such as China, India, and Japan are creating lucrative opportunities for cyclosporine market expansion in the region.
   
• As the demand for effective treatment options rises, the Asia Pacific market is poised for robust growth in the coming years.
   

India presents significant growth potential in the cyclosporine market.
 

• India has significant growth potential in the cyclosporine industry, driven by factors such as the increasing prevalence of autoimmune diseases, organ transplantations, and the growing demand for immunosuppressive therapies.
   
• In 2023, India achieved significant milestones in organ transplantation with a total of 18,378 organ transplants.
   
• The growing number of patients requiring long-term immunosuppressive treatment, particularly following organ transplants, is creating substantial market opportunities.
   
• Additionally, India’s cost-effective production of generic cyclosporine also positions it as a key player in both domestic and international markets, further supporting the market's expansion.
   

Latin America Cyclosporine Market
 

Brazil's cyclosporine industry is projected to witness growth in the coming years.
 

• The country's large patient population, coupled with improving access to healthcare services and treatments, is driving the adoption of immunosuppressive therapies like cyclosporine.
   
• Additionally, the government's efforts to improve the healthcare system and regulatory support for pharmaceutical innovations further contribute to the market's growth potential.
   
• With a growing focus on improving treatment options for conditions such as rheumatoid arthritis and psoriasis, Brazil is poised to witness significant growth in the market in the coming years.
   

Middle East & Africa Cyclosporine Market
 

Saudi Arabia is expected to witness strong growth in the market, supported by expanding transplant activity, rising ocular disease burden, and ongoing healthcare system development.
 

• Government data indicate that 2,091 organs were transplanted in Saudi Arabia in 2023 from both living and deceased donors, highlighting a growing patient population requiring long-term immunosuppressive therapy. In parallel, epidemiological studies report an elevated risk of dry eye disease in the country due to environmental factors, with the prevalence of DED ranging from 32.1% to 75.9%.
   
• Combined with increasing investment in specialized healthcare centers and transplant infrastructure across the country, Saudi Arabia is a high-growth market for cyclosporine within the Middle East region.
   

Cyclosporine Market Share

The competitive landscape in the cyclosporine industry is characterized by a mix of established pharmaceutical companies and emerging players, all vying for market share in the immunosuppressant drug segment. The top 5 players, including AbbVie, Novartis, Sun Pharmaceutical, Teva, and Santen Pharmaceutical, hold a collective market share of ~38%. The market is also witnessing intensifying competition from generic manufacturers following patent expirations of several cyclosporine formulations, leading to pricing pressure and broader product availability across regions.
 

In addition, companies are increasingly focusing on formulation innovation, lifecycle management strategies, and expansion into specialty ophthalmology indications to sustain differentiation and revenue growth. Strategic initiatives such as partnerships, geographic expansion in emerging markets, and regulatory approvals for new or improved delivery technologies are further shaping competitive dynamics. Moreover, the presence of regional manufacturers and branded generic suppliers continues to create a long tail of competitors, reinforcing the market’s moderately fragmented structure while driving accessibility and volume growth globally.
 

Cyclosporine Market Companies

Some of the prominent players operating in the cyclosporine industry include:

• Amneal Pharmaceuticals

• Avet Pharmaceuticals
• AdvaCare Pharma
• AbbVie
• Apotex
• Bora Pharmaceuticals
• Cipla
• Dr. Reddy's Laboratories
• Novartis
• Santen Pharmaceutical
• Sun Pharmaceutical Industries
• Strides Pharma Science Limited
• Teva Pharmaceutical Industries
• Viatris
  
   
• Abbvie

AbbVie is a key participant in the cyclosporine market through its ophthalmology portfolio, particularly with cyclosporine ophthalmic formulations widely prescribed for dry eye disease and ocular surface inflammation. The company’s strong specialty care network, established physician familiarity, and continued lifecycle management efforts support sustained utilization of cyclosporine in chronic eye care settings.
 

• Novartis

Novartis holds a foundational position in the cyclosporine market as the original developer of cyclosporine products used in solid organ transplantation and autoimmune disorders. Its long-standing presence in transplant medicine, combined with global clinical adoption of its cyclosporine formulations, continues to reinforce its relevance in maintenance immunosuppression therapy worldwide.
 

Cyclosporine Industry News

• In January 2026, Bora Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved its cyclosporine ophthalmic emulsion 0.05%, a sterile single-use formulation supplied in vials. The approval strengthens Bora’s ophthalmic pipeline and increases generic availability of cyclosporine therapies for dry eye disease, contributing to intensifying competition within the ophthalmic cyclosporine market.
   
• In December 2025, Amneal Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved its cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product serves as a generic equivalent to Restasis, expanding Amneal’s complex ophthalmic portfolio and intensifying generic competition in the dry eye disease treatment segment.
   
• In August 2022, Strides Pharma Science Limited received approval from the U.S. Food and Drug Administration (USFDA) for its Cyclosporine Softgel Capsules USP, available in 25 mg, 50 mg, and 100 mg dosages. This marks a significant milestone as Strides is the first Indian company to gain approval for this product, enhancing its immunosuppressant portfolio in the US market.
   

The cyclosporine market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Indication

• Transplant rejection prophylaxis
• Rheumatoid arthritis
• Psoriasis
• Autoimmune myasthenia gravis
• Dry eye
• Other indications

Market, By Dosage Form

• Capsules
• Eye drops
• Solutions
• Creams and ointments

Market, By Route of Administration

• Oral
• Topical
• Parenteral

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE